Evidence map›Paper›PMID 40191014›Full record

ArticleGastroenterology & hepatology2024

Rationale for an Eosinophilic Esophagitis Treat-to-Target Concept.

Thomas Greuter, Alex Straumann

Abstract read
In one paragraph

Article in Gastroenterology & hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thomas GreuterDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland.
Alex StraumannDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilic esophagitis (EoE) is a chronic T helper 2-mediated inflammatory disorder of the esophagus defined clinically by the presence of symptoms of esophageal dysfunction and histologically by an eosinophil-predominant infiltration. Correspondingly, treatment has aimed at controlling both symptom severity and histologic activity. However, with emerging clinical and pathophysiologic understanding of the disease, it has become increasingly apparent that other disease aspects need to be targeted as well, such as endoscopic severity and quality of life. Moreover, with the role of eosinophils having been questioned lately, histologic changes beyond eosinophil infiltration have come to attention and are captured by newly validated scores. In addition, EoE is being increasingly considered a transmural disease that cannot be assessed by simple endoscopy but needs measurement of esophageal distensibility, a surrogate marker for fibrosis. Finally, novel tools such as measurement of esophageal impedance could make it possible to assess for complete restoration of the esophageal epithelium, potentially corresponding to disease clearance. This article reviews the various outcome parameters in adult EoE management and proposes an algorithm for a treat-to-target concept, in analogy to what has been practiced in inflammatory bowel disease treatment for the last 10 years.

Indexed as

disease clearanceEosinophilic esophagitisremissiontreat-to-target algorithmvalidated scores

Identifiers

PMID40191014
PMCPMC11966228

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.